Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41408-018-0067-6 http://scihub22266oqcxt.onion/10.1038/s41408-018-0067-6 C5841331!5841331!29515114     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood+Cancer+J 2018 ; 8 (3): ä Nephropedia Template TP {{tp|p=29515114|t=2018. Momelotinib therapy for myelofibrosis: a 7-year follow-up |pdf=|usr=}}{{29515114}} gab.com Text Momelotinib therapy for myelofibrosis: a 7-year follow-up JO: Blood Cancer J http://www.kidney.de/pget.php?&tw=1&pmid=29515114 #FOAvip One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinued in 91% of the patients, after a median treatment duration of 1.4 years. Grade 3/4 toxicity included thrombocytopenia (34%) and liver/pancreatic test abnormalities (<10%); grade 1/2 peripheral neuropathy occurred in 47%. Clinical improvement (CI) occurred in 57% of patients, including 44% anemia and 43% spleen response. CI was more likely to occur in ASXL1-unmutated patients (66% vs 44%) and in those with <2% circulating blasts (66% vs 42%). Response was more durable in the presence of CALR type 1/like and absence of very high-risk karyotype. In multivariable analysis, absence of CALR type 1/like (HR 3.0; 95% CI 1.2?7.6) and presence of ASXL1 (HR 1.9; 95% CI 1.1?3.2) or SRSF2 (HR 2.4, 95% CI 1.3?4.5) mutations adversely affected survival. SRSF2 mutations (HR 4.7, 95% CI 1.3?16.9), very high-risk karyotype (HR 7.9, 95% CI 1.9?32.1), and circulating blasts ?2% (HR 3.9, 95% CI 1.4?11.0) predicted leukemic transformation. Post-MMB survival (median 3.2 years) was not significantly different than that of a risk-matched MF cohort not receiving MMB. Twit Text FOAVip Momelotinib therapy for myelofibrosis: a 7-year follow-up ????Blood Cancer J http://www.kidney.de/pget.php?&tw=1&pmid=29515114 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29515114 #FOAvip English Wikipedia <ref>{{Cite pmid|29515114}}</ref> Momelotinib therapy for myelofibrosis: a 7-year follow-up #MMPMID29515114 Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A Blood Cancer J 2018[Mar]; 8 (3): ä PMID29515114show ga One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. As of July 2017, MMB was discontinued in 91% of the patients, after a median treatment duration of 1.4 years. Grade 3/4 toxicity included thrombocytopenia (34%) and liver/pancreatic test abnormalities (<10%); grade 1/2 peripheral neuropathy occurred in 47%. Clinical improvement (CI) occurred in 57% of patients, including 44% anemia and 43% spleen response. CI was more likely to occur in ASXL1-unmutated patients (66% vs 44%) and in those with <2% circulating blasts (66% vs 42%). Response was more durable in the presence of CALR type 1/like and absence of very high-risk karyotype. In multivariable analysis, absence of CALR type 1/like (HR 3.0; 95% CI 1.2?7.6) and presence of ASXL1 (HR 1.9; 95% CI 1.1?3.2) or SRSF2 (HR 2.4, 95% CI 1.3?4.5) mutations adversely affected survival. SRSF2 mutations (HR 4.7, 95% CI 1.3?16.9), very high-risk karyotype (HR 7.9, 95% CI 1.9?32.1), and circulating blasts ?2% (HR 3.9, 95% CI 1.4?11.0) predicted leukemic transformation. Post-MMB survival (median 3.2 years) was not significantly different than that of a risk-matched MF cohort not receiving MMB. äMomelotinib therapy for myelofibrosis: a 7-year follow-up (epmc).pdf DeepDyve Pubget Overpricing